KLRK1 and acute myeloid leukemia: In AML patients’ serum the presence of soluble NKG2D-L (MICA, MICB and ULBP2) is associated with a down-regulation of the surface NKG2D expression leading to an impairment in NKG2D-mediated NK-cell activity [77].